Refractec CK Presbyopia Treatment Should Be Limited To 2.25D – FDA Panel
This article was originally published in The Gray Sheet
Executive Summary
Refractec's CK Blended Vision radio frequency procedure should be approved to treat a narrower range of presbyobia than sought by the company, FDA's Ophthalmic Devices Panel recommended Feb. 6